Literature DB >> 2527529

Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

W Fischli1, F Hefti, J P Clozel.   

Abstract

1. The effects of acute and chronic treatment with cilazapril, a new ACE inhibitor, on peripheral vasculature and renal excretory function were assessed in spontaneously hypertensive rats. Regional blood flow and cardiac output were measured by the radioactive microspheres technique. 2. Acute treatment (3 mg kg-1 intravenously) reduced mean arterial blood pressure from 171 +/- 7 to 140 241 +/- 7 mm Hg (P less than 0.001), chronic treatment (1 x 10 mg kg-1 day-1 orally for 9 weeks) from 191 +/- 5 to 122 +/- 3 mm Hg P less than 0.001). With both kinds of treatments cardiac output was unchanged. Heart rate was slightly decreased (-9%, P less than 0.05) with chronic treatment. Acutely, the main effect of cilazapril was a decrease of the renal vascular resistance (-41%, P less than 0.001) associated with an increase of the fraction of the cardiac output distributed to the kidney (+46%, P less than 0.001). Chronically, cilazapril decreased regional vascular resistance in most of the peripheral vascular beds except the heart. 3. With a high dose of cilazapril (10 mg kg-1 orally) both acute and chronic treatment increased diuresis (+107% and +92%, P less than 0.001) and natriuresis (/124% and +111%, P less than 0.001) with a slight increase in kaliuresis. However, with a low dose (1 mg kg-1 orally) the kidneys responded only to chronic treatment. 4. It is concluded that chronic treatment with cilazapril decreases arterial blood pressure more than acute treatment. This effect seems to be due to a greater peripheral vasodilation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527529      PMCID: PMC1379742          DOI: 10.1111/j.1365-2125.1989.tb03476.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.

Authors:  R J Laffan; M E Goldberg; J P High; T R Schaeffer; M H Waugh; B Rubin
Journal:  J Pharmacol Exp Ther       Date:  1978-02       Impact factor: 4.030

2.  Blood flow measurements with radionuclide-labeled particles.

Authors:  M A Heymann; B D Payne; J I Hoffman; A M Rudolph
Journal:  Prog Cardiovasc Dis       Date:  1977 Jul-Aug       Impact factor: 8.194

3.  The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance.

Authors:  W R McNabb; F H Noormohamed; A F Lant
Journal:  J Hypertens       Date:  1986-02       Impact factor: 4.844

4.  Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Authors:  S A Atlas; D B Case; J E Sealey; J H Laragh; D N McKinstry
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

5.  Similarities of genetic (spontaneous) hypertension. Man and rat.

Authors:  N C Trippodo; E D Frohlich
Journal:  Circ Res       Date:  1981-03       Impact factor: 17.367

6.  Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

Authors:  D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

7.  Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.

Authors:  N K Hollenberg; S L Swartz; D R Passan; G H Williams
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

8.  Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR.

Authors:  H Koike; K Ito; M Miyamoto; H Nishino
Journal:  Hypertension       Date:  1980 May-Jun       Impact factor: 10.190

9.  Captopril and hypertension development in the SHR.

Authors:  J F Giudicelli; J L Freslon; S Glasson; C Richer
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

10.  Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225).

Authors:  R A Ferrone; M J Antonaccio
Journal:  Eur J Pharmacol       Date:  1979-12-07       Impact factor: 4.432

View more
  3 in total

Review 1.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Vascular protection with cilazapril.

Authors:  J P Clozel; J S Powell; H Kuhn; R K Müller; F Hefti; H R Baumgartner
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Clinical pharmacology of cilazapril.

Authors:  C H Kleinbloesem; P van Brummelen; R J Francis; U W Wiegand
Journal:  Drugs       Date:  1991       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.